|Low-molecular-weight heparin and other antithrombotic agents in the setting of a fast-track revascularization in unstable coronary artery disease.|
|PMID: 11251354 Owner: NLM Status: MEDLINE|
|Revascularization procedures and particularly percutaneous transluminal coronary angioplasty are being performed more and more often in patients with unstable coronary artery disease, despite the fact that these procedures are known to carry a higher risk in such patients than in those with stable disease. This article reviews studies that have investigated the potential of modern antithrombotic therapy -- low-molecular-weight heparin, anti-Xa agents, direct antithrombin inhibitors and glycoprotein IIb/IIIa inhibitors -- to reduce the post-procedural event rate in such patients. The results are promising.|
|J P Bassand|
Related Documents :
|6112564 - Trial of heparin versus atenolol in prevention of myocardial infarction in intermediate...
7850674 - What do we really know about secondary prevention after myocardial infarction?
9894704 - Changing prescribing behaviour: early low dose aspirin in suspected acute myocardial in...
10762894 - High pressure coronary stenting: efficacy and safety of aspirin versus coumadin plus as...
15100754 - Geographical location of residence and uniformity of access to cardiac revascularizatio...
9412884 - Association between r-wave amplitude of the electrocardiogram and myocardial function d...
|Type: Journal Article; Review|
|Title: Haemostasis Volume: 30 Suppl 2 ISSN: 0301-0147 ISO Abbreviation: Haemostasis Publication Date: 2000|
|Created Date: 2001-03-19 Completed Date: 2001-07-05 Revised Date: 2013-05-24|
Medline Journal Info:
|Nlm Unique ID: 0371574 Medline TA: Haemostasis Country: Switzerland|
|Languages: eng Pagination: 114-21; discussion 106-7 Citation Subset: IM|
|Copyright 2001 S. Karger AG, Basel|
|Department of Cardiology, University Hospital Jean-Minjoz, Besançon, France. email@example.com|
|APA/MLA Format Download EndNote Download BibTex|
Angioplasty, Balloon, Coronary
Antibodies, Monoclonal / therapeutic use
Anticoagulants / administration & dosage, therapeutic use*
Aspirin / administration & dosage, therapeutic use
Clinical Trials as Topic
Combined Modality Therapy
Drug Therapy, Combination
Factor Xa / antagonists & inhibitors
Heparin, Low-Molecular-Weight / administration & dosage, therapeutic use*
Hirudins / administration & dosage, analogs & derivatives
Immunoglobulin Fab Fragments / therapeutic use
Oligosaccharides / administration & dosage, therapeutic use
Peptide Fragments / administration & dosage, therapeutic use
Peptides / therapeutic use
Platelet Aggregation Inhibitors / administration & dosage, therapeutic use
Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors
Postoperative Complications / prevention & control
Randomized Controlled Trials as Topic
Recombinant Proteins / administration & dosage, therapeutic use
Thrombocytopenia / chemically induced
Thrombosis / prevention & control*
Tyrosine / analogs & derivatives*, therapeutic use
|0/Antibodies, Monoclonal; 0/Anticoagulants; 0/Heparin, Low-Molecular-Weight; 0/Hirudins; 0/Immunoglobulin Fab Fragments; 0/Oligosaccharides; 0/PENTA; 0/Peptide Fragments; 0/Peptides; 0/Platelet Aggregation Inhibitors; 0/Platelet Glycoprotein GPIIb-IIIa Complex; 0/Recombinant Proteins; 0/eptifibatide; 128270-60-0/bivalirudin; 144494-65-5/tirofiban; 50-78-2/Aspirin; 55520-40-6/Tyrosine; EC 188.8.131.52/Factor Xa; X85G7936GV/abciximab|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Low-molecular-weight heparin as a bridge to timely revascularization in unstable coronary artery dis...
Next Document: Low-molecular-weight heparin and other antithrombotic agents in the setting of a primarily medical t...